Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

New antibody can be used as early diagnostic tool for Parkinson's

New antibody can be used as early diagnostic tool for Parkinson's

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Dyax second quarter 2012 total revenues increase to $14.0 million

Dyax second quarter 2012 total revenues increase to $14.0 million

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

Merck, OMT announce new antibody discovery collaboration

Merck, OMT announce new antibody discovery collaboration

Anti-cancer activity of HuCAL antibody revealed by new data from OncoMed

Anti-cancer activity of HuCAL antibody revealed by new data from OncoMed

NOTCH1 signaling promotes T-cell acute lymphoblastic leukemia-initiating cell regeneration

NOTCH1 signaling promotes T-cell acute lymphoblastic leukemia-initiating cell regeneration

Study identifies possible new approach to defeat bacterial infections

Study identifies possible new approach to defeat bacterial infections

New platform for analysis of next generation sequencing data developed by Compugen

New platform for analysis of next generation sequencing data developed by Compugen

Researchers use DNA molecules to stimulate repair of nerve coatings that mimic MS

Researchers use DNA molecules to stimulate repair of nerve coatings that mimic MS

Vaccine for nicotine addiction developed

Vaccine for nicotine addiction developed

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.